Rain Oncology to Report First Quarter 2023 Financial Results and Highlights Recent Progress on May 11, 2023

Rhea-AI Summary

Rain Oncology Inc. (NASDAQ: RAIN) announced that it will report its first quarter financial results for the period ending March 31, 2023, along with updates on its business on May 11, 2023. The company is focused on developing precision oncology therapeutics, particularly its lead candidate, milademetan, which inhibits the MDM2-p53 complex to reactivate p53. A conference call and webcast will follow the earnings release, scheduled for 2:00 PM PT (5:00 PM ET) on the same day. Investors can access the call via phone or through the provided webcast link. Rain's strategy involves a tumor-agnostic approach, selecting patients based on tumor genetics.

Positive

• Upcoming earnings report may provide insights into financial performance and business progress.
• Lead product candidate, milademetan, targets p53 reactivation and shows potential in oncology.

Negative

• None.

NEWARK, Calif., April 24, 2023 (GLOBE NEWSWIRE) -- Rain Oncology Inc. (NasdaqGS: RAIN), (“Rain”), a late-stage biotechnology company developing precision oncology therapeutics with a lead product candidate, milademetan, an oral, small molecule inhibitor of the MDM2-p53 complex that reactivates p53, today announced it will report financial results for the first quarter ended March 31, 2023 and highlights of recent progress on Thursday, May 11, 2023. On that day, management will host a conference call and webcast at 2:00 pm PT (5:00 pm ET) to discuss the Company’s business and financial results.

Conference Call and Webcast Details:
Date: May 11, 2023
Time: 2:00 pm PT (5:00 pm ET)
Dial In Numbers: 1 (877) 704-4453 (U.S. Toll Free) / 1 (201) 389-0920 (International)
Conference ID: 13738120
Webcast Link: https://viavid.webcasts.com/starthere.jsp?ei=1610065&tp_key=22d79acd4c

A replay of the call will be available by visiting the "Events" section of the Rain website after the conclusion of the presentation and will be archived on the Rain website for 30 days.

About Rain Oncology Inc.
Rain Oncology Inc. is a late-stage precision oncology company developing therapies that target oncogenic drivers for which it is able to genetically select patients it believes will most likely benefit. This approach includes using a tumor-agnostic strategy to select patients based on their tumors’ underlying genetics rather than histology. Rain’s lead product candidate, milademetan, is a small molecule, oral inhibitor of MDM2-p53 complex that reactivates p53.

Media Contact
Jordyn Temperato
LifeSci Communications
jtemperato@lifescicomms.com

Investor Contact
Dan Ferry
LifeSci Advisors
+1.617.430.7576
daniel@lifesciadvisors.com

FAQ

When will Rain Oncology report its financial results for Q1 2023?

Rain Oncology will report its Q1 2023 financial results on May 11, 2023.

What is Rain Oncology's lead product candidate?

Rain Oncology's lead product candidate is milademetan, an oral inhibitor of the MDM2-p53 complex.

What time is Rain Oncology's conference call on May 11, 2023?

The conference call is scheduled for 2:00 PM PT (5:00 PM ET) on May 11, 2023.

How can I access the webcast for Rain Oncology's earnings call?

The webcast can be accessed through the link provided in the press release.

What strategy does Rain Oncology use for patient selection?

Rain Oncology employs a tumor-agnostic strategy, selecting patients based on their tumors' underlying genetics.